Amid a push to resolve opioid and talc claims, Johnson & Johnson settles Risperdal litigation for $800M

Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its opioid and talc products. Friday brought word of a lower-profile resolution, as J&J revealed it has settled liability claims surrounding its antipsychotic drug Risperdal.